Will the company take another steep dividend increase? Will the company embark on a more sizeable share buyback program? Will the company make any corporate acquisitions? Pfizer could conceivably do all of the above.
One aspect of the Pfizer story that is more difficult to nail down is how the company will use its sizeable cash hoards.